Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

APP-C31 pathology as a target in neurodegenerative diseases.

Journal of biomedical science·2026
Same author

Hope for vascular cognitive impairment: Ac-YVAD-cmk as a novel treatment against white matter rarefaction.

PloS one·2024
Same author

Mechanisms of biased agonism by Gα<sub>i/o</sub>-biased stapled peptide agonists of the relaxin-3 receptor.

Science signaling·2024
Same author

The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank.

Pharmaceuticals (Basel, Switzerland)·2023
Same author

The putative role of the relaxin-3/RXFP3 system in clinical depression and anxiety: A systematic literature review.

Neuroscience and biobehavioral reviews·2021
Same author

A Flexi-PEGDA Upconversion Implant for Wireless Brain Photodynamic Therapy.

Advanced materials (Deerfield Beach, Fla.)·2020

Related Experiment Video

Updated: May 29, 2025

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps
09:30

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps

Published on: July 19, 2024

1.2K

Biased agonism in peptide-GPCRs: A structural perspective.

Tharindunee Jayakody1, Dinath Kavishka Budagoda1, Krishan Mendis1

  • 1Department of Chemistry, University of Colombo, P.O. Box 1490, Colombo 00300, Sri Lanka.

Pharmacology & Therapeutics
|January 31, 2025
PubMed
Summary

G protein-coupled receptors (GPCRs) form complexes to signal inside cells. This review explores biased agonism in peptide-GPCRs, focusing on structural insights and therapeutic potential for new drugs.

Keywords:
Biased agonismG proteinG protein coupled receptorPeptideβ-arrestin

More Related Videos

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

18.7K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.8K

Related Experiment Videos

Last Updated: May 29, 2025

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps
09:30

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps

Published on: July 19, 2024

1.2K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

18.7K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.8K

Area of Science:

  • Molecular pharmacology
  • Structural biology
  • Drug discovery

Background:

  • G protein-coupled receptors (GPCRs) are key cell membrane proteins that mediate signal transduction.
  • Peptide ligands bind to GPCRs, forming a ternary complex critical for cellular responses.
  • Allosterism in GPCRs enables biased agonism, a phenomenon with therapeutic implications.

Purpose of the Study:

  • To review the structural basis of signaling bias in peptide-GPCRs (Classes A and B).
  • To discuss the therapeutic relevance of biased agonism at peptide-GPCRs.
  • To guide the development of novel biased peptide drugs.

Main Methods:

  • Literature review focusing on structural and pharmacological studies of peptide-GPCRs.
  • Analysis of allosteric mechanisms underlying biased agonism.
  • Examination of therapeutic applications and drug development strategies.

Main Results:

  • Signaling bias is observed in peptide-GPCRs, influenced by ligand interactions and receptor structure.
  • Structural insights reveal how allosterism dictates biased signaling pathways.
  • Biased agonism at peptide-GPCRs offers opportunities for developing targeted therapeutics with improved safety profiles.

Conclusions:

  • Understanding the structural basis of bias is crucial for designing selective peptide drugs.
  • Biased agonism in peptide-GPCRs holds significant therapeutic promise.
  • Further research into biased peptide-GPCRs could lead to novel treatments for various diseases.